|
|
Vol. 26.22 – 1 December, 2025
|
|
|
|
|
|
|
Investigators demonstrated that endowing CAR T cells with ectopic interleukin (IL)-9 signaling by co-expressing an IL-9 receptor rewires CAR T cell fate under antigen stress to enhance antitumor efficacy. [Immunity]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Researchers reported an in situ CAR-macrophage therapy. By leveraging lipid nanoparticles designed to selectively transfect tumor-associated macrophages, they circumvent extensive ex vivo manipulation and achieve robust CAR expression directly within the tumor microenvironment.
[ACS Nano]
|
|
|
|
|
|
The authors presented an engineered yeast-based antigen system for the simulation of cancer cells with precise regulation of surface-antigen densities, providing a tool for controlled activation of CAR T cells and systematic assessment of antigen density effects.
[Nature Communications]
|
|
|
|
|
|
Scientists described a multifaceted approach to engineer allogeneic CAR T cells resistant to both biochemical and immunological inhibitory signaling using an adenine base editor and a CRISPR-Cas12b nuclease. [Nature Communications]
|
|
|
|
|
|
Researchers developed autologous anti-B-cell maturation antigen (BCMA) and CD19 bispecific CAR T cells to evaluate the safety and efficacy in refractory myasthenia gravis.
[EClinicalMedicine]
|
|
|
|
|
|
Scientists identified the accumulation of epithelial urokinase plasminogen activator receptor (uPAR)-positive cells in the aging gut and uncovered their impact on intestinal stem cells function in aging. [Nature Aging]
|
|
|
|
|
|
Investigators reported that monotherapy using base-edited “universal” donor CAR T cells against CD33, CLL-1, or CD7 delivered inhibition of acute myeloid leukemia in immunodeficient mice when antigen expression was homogenous. [Leukemia]
|
|
|
|
|
|
Researchers developed an off-the-shelf immunotherapy using gene-engineered natural killer T cells derived from stem cells called Allo15MCAR-NKT cells.
[Proceedings of The National Academy of Sciences of The United States of America]
|
|
|
|
|
|
An effective CAR-T-associated coagulopathy (CARAC) risk prediction and stratification model was established. High-risk CARAC patients, particularly CARAC-disseminated intravascular coagulation, were associated with significantly worse outcomes.
[Thrombosis Research]
|
|
|
|
|
|
Investigators evaluated the capacity of two tyrosine kinase inhibitors, dasatinib and ponatinib, to reversibly inhibit CAR T cell functions. [Molecular Therapy Oncology]
|
|
|
|
|
|
|
|
The authors discuss the current situation of CAR-T therapies in the clinical treatment of lymphoma patients, the mechanisms of CAR-T cell exhaustion, and potential strategies to overcome CAR-T cell exhaustion, thereby bringing hope to improve therapeutic outcomes for lymphoma patients. [Molecular Therapy Oncology]
|
|
|
|
|
|
|
|
Physician and cancer researcher Mirco Julian Friedrich from the German Cancer Research Center (DKFZ), the stem cell research institute HI-STEM*, and Heidelberg University Hospital has received two awards for two independent research projects.
[DKFZ]
|
|
|
|
|
|
Novartis announced that the US FDA has approved Itvisma® for the treatment of children two years and older, teens, and adults living with SMA with a confirmed mutation in the survival motor neuron 1 gene, making it the first and only gene replacement therapy available for this broad population. [Novartis]
|
|
|
|
|
|
|
|
February 4-5, 2026 Cambridge, England, United Kingdom
|
|
|
|
|
|
|
|
|
|
|
The University of Iowa – Iowa City, Iowa, United States
|
|
|
|
|
|
|
Midwestern University – Glendale, Arizona, United States
|
|
|
|
|
|
|
St Jude Children’s Research Hospital – Memphis, Tennessee, United States
|
|
|
|
|
|
|
Fred Hutchinson Cancer Center – Seattle, Washington, United States
|
|
|
|
|
|
|
Baylor College of Medicine – Houston, Texas, United States
|
|
|
|
|
|